Neuphoria Therapeutics NEUP
NASDAQ NEUP
$3.47 -0.04 (-1.14%)
As of: Oct 2, 2026 · 3:54 PM EDT

Neuphoria Therapeutics (NEUP) Return on Sales [ROS] (2024 - 2025)

Updated

Neuphoria Therapeutics' Return on Sales [ROS] came in at -1401.09% for FY2026 (year ended Jun 30, 2026), down 1393.87 percentage points from -7.21% in FY2025.

Analysis

Neuphoria Therapeutics (NEUP) Return on Sales [ROS] (2024 - 2025) Analysis & Trends

Going back to FY2020, Neuphoria Therapeutics' Return on Sales [ROS] data covers 5 fiscal years.

  • Return on Sales [ROS] carries a four-year change of +6908.54 percentage points (FY2022 to FY2026).
  • The FY2026 figure represents the lowest annual Return on Sales [ROS] since FY2023.
  • Per Business Quant, earlier fiscal years put Return on Sales [ROS] at -7.21% in FY2025, -145255.68% in FY2023 (-136946.05 pp) and -8309.63% in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 28.21%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 37.86%
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -3.52%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 32.97%
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 20.57%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 34.95%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -133.21%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 28.37%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 37.40%
10 Neuphoria Therapeutics 443.79 Mn 368.60 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 79.85%
Dec 31, 2024 -558.84%
API Access

Neuphoria Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=NEUP&period=max&api_key=YOUR_API_KEY